Billionaire Profile
Karin Sartorius-Herbst
Global Rank
#1771

Image: Unsplash Contributor | Unsplash License | via Unsplash

Karin Sartorius-Herbst

CEO, Biopharmaceuticals
GERMANY
Real-Time Net Worth
$2.324B
Estimated based on Biopharmaceuticals stock value as of March 6, 2026
-2.61% (24h)
Age
83
Source
Biopharmaceuticals
Industry
Healthcare
Citizenship
GERMANY

Biography

Karin Sartorius-Herbst, a German biopharmaceutical heiress, is currently estimated to have a net worth of $2.4 billion. At 83 years old, she inherited a significant stake in Sartorius AG, a company founded by her great-grandfather, which manufactures pharmaceutical and laboratory equipment. Her career has been intertwined with the family business, with her actively involved in various aspects of the company's development, particularly after the death of her father, Horst Sartorius, in 1998. Although she has never held an official leadership position, she has been described as the "Social Minister" of the company, underscoring her role in social and cultural matters within Sartorius AG. She holds a degree in economics from the University of Goettingen.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life

Karin Sartorius-Herbst was born into a family with a rich history connected to the evolution of Sartorius AG. Her great-grandfather, Florenz Sartorius, established a precision engineering workshop in Göttingen in 1870. This workshop specialized in the production of analytical balances and later evolved into a globally leading life science corporation.

Rise to Success

After the death of her father, Horst Sartorius, in 1998, Karin Sartorius-Herbst became a member of the community of heirs and currently holds a third of the shares. In 2021, she increased her stake within the community of heirs. She has played a significant role in the company's evolution, contributing to the expansion and advancement of Sartorius AG over the years.

Key Business Strategies

Karin Sartorius-Herbst has contributed to various changes and developments in the company, including its IPO in the 1990s, which helped sustain growth and diversify its financing. Despite her substantial involvement with Sartorius AG, she consciously chose not to assume a formal leadership role. She has mentioned that she sees herself as the company's "Social Minister", highlighting her role in the company's social and cultural affairs.

Philanthropy

While specific details on philanthropy are unavailable, her role as the heiress to a large biopharmaceutical fortune likely involves charitable activities.

Career Milestones

1990

Sartorius AG IPO

Contributed to the expansion and development of Sartorius AG.

1998

Inheritance

Inherited a stake in Sartorius AG after her father's death.

2021

Increased Stake

Increased her stake within the community of heirs.